Summary of Significant Accounting Policies (Details) $ in Thousands		1 Months Ended		3 Months Ended	9 Months Ended
	May 09, 2017 shares	May 31, 2017 USD ($) shares	Feb. 29, 2016 shares	Jul. 31, 2016 shares	Sep. 30, 2017 USD ($) director	Oct. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Restricted Cash
Restricted Cash Current							$ 67
Restricted Cash Non Current					$ 0		60
Security deposit returned					$ 60
Deferred Offering Costs
Deferred offering costs							134
Warrant Liability
Number of directors to whom the Company agreed to issue warrants | director					2
Derivative Liability
Fair value of derivative liability					$ 0	$ 0	512
Contingent Equity Liability
Issuance of common shares | shares			429,000	1,090,500
Certificate of deposit
Restricted Cash
Restricted Cash Non Current							60
Series A preferred shares
Restricted Cash
Restricted Cash Current					$ 0		$ 67
IPO
Contingent Equity Liability
Issuance of common shares | shares	9,900,000
Fair value of contingent equity liabilities		$ 32,020
Product related collaborative arrangements | BMS Agreement
Contingent Equity Liability
Issuance of common shares | shares		1,345,374
Product related collaborative arrangements | BMS Agreement | IPO
Contingent Equity Liability
Issuance of common shares | shares		1,345,374
Product related collaborative arrangements | AstraZeneca
Contingent Equity Liability
Issuance of common shares | shares		538,149
Product related collaborative arrangements | AstraZeneca | IPO
Contingent Equity Liability
Issuance of common shares | shares		538,149